Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Deep Sequencing Analysis Leads to Major Genetic Discoveries at Hadassah

Using a deep sequencing analyzer, Prof. Orly Elpeleg, Director of the Hadassah Medical Organization’s Department of Genetic and Metabolic Diseases, and her colleagues have determined the sequence of millions of DNA fragments simultaneously--8,000 times the capacity of the former generation of DNA sequencing machines. This has enabled Hadassah’s researchers to identify important gene mutations that cause severe metabolic diseases and to counteract their devastating effects.

In the last three years alone, Prof. Elpeleg and her team have identified 30 genes responsible for some of the most disabling--and sometimes deadly--children’s diseases, making Hadassah one of the top ten centers in the world to identify disease-causing gene mutations. For example, using deep sequence analysis, Hadassah researchers discovered a protein gene responsible for a rare form of infant paralysis affecting Jews who originally came from North Africa. When both parents pass the gene on to their child, the infant suffers muscle paralysis after an illness involving a fever. Prof. Dror Mevorach, Director of Hadassah’s Center for Research in Rheumatology and head of Internal Medicine Department B, has worked on this same protein for the past 15 years. He proposed treating these infants with a synthetic experimental drug that has proven effective in fighting a similar rare disease. The first four babies discovered to have the paralysis have been given this drug, yielding very good results.

Compassionate, well-trained staff coupled with cutting-edge technology makes rehabilitative care at HMO world-class . Patients who suffer a stroke or traumatic brain injury, or have orthopedic or neuromuscular conditions, are among the primary beneficiaries of the multidisciplinary rehabilitation care at Mount Scopus.

DONATE

Join

Advocate

Lead

LEARN MORE

View all of our Impact Areas

The defective gene, carried by 1 in 66 people of North African origin, causes a defect in the protein that acts as a “brake” in the immune system to prevent endless firing against the illness. Instead, the defective gene allows the awakened immune reaction to continue, compromising the baby’s myelin (the coating of the nerves), which affects the transmission of signals from the spinal cord to the muscles of the limbs. (For further information, see the January 2013 issue of Blood.)

Date: 1/24/2014

Her Excellency Marie Bashir Sees Bridges to Peace at Hadassah's Hospitals

Hadassah Researcher Honored with Prestigious Prize for Blood Discovery

IVF Babies: A Gift of Israel and Hadassah to Its People

Healing Garden at Hadassah's Hospitals Dedicated to Smorgon Family

International Symposium on Pancreatic Disease Headed Up by Hadassah Specialist

BioLineRx to Commence Phase 1 Stem Cell Trial at Hadassah Medical Organization

Hadassah’s Prof. Eitan Kerem Receives European Cystic Fibrosis Society 2014 Prize

Hadassah's School Awarded 2014 National Education Award

International “No Smoking Day 2014” at Hadassah's Hospitals

Mid-Workout, Hadassah Doctor Sprints to Save a Life

Going Local: Heads of Hadassah’s ERs Forge Bond with Community Pediatricians

Hadassah Doctors Initiate Medical Collaborations in Australia

Hadassah’s Innovative Cardiac Protocol Saves Man’s Life

International Orthopedic Society Invites Hadassah Medical Organization as Member

New Trial Data out of Hadassah Hospitals Show Promise for Stem Cell Treatment of ALS

Oncology Patient Raves About Exceptional Treatment at Hadassah

Ugandan HIV-Positive Orphans Saved by Hadassah Global Outreach

Growing Heart Healthy Kids in the Heart of East Jerusalem

PHOTOS: The Pope Visits Hadassah Hospitals

Prof. Alexander Margulis: Hadassah Pediatric Plastic Surgeon and Israel Navy Seal



More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America